Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Identification of hypoxic gene-signature as a prognostic and predictive biomarker to determine effective therapy in high risk bladder cancer patients.

Tan Z, D'Costa NM, Raven PA, Chavez-Munoz C, So AI.

Transl Androl Urol. 2018 Mar;7(Suppl 1):S104-S106. doi: 10.21037/tau.2017.12.17. No abstract available.

2.

A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer.

Frees SK, Aning J, Black P, Struss W, Bell R, Chavez-Munoz C, Gleave M, So AI.

World J Urol. 2018 Feb;36(2):215-220. doi: 10.1007/s00345-017-2109-2. Epub 2017 Nov 7.

PMID:
29116394
3.

Surgical placement of rectus sheath catheters in a cadaveric cystectomy model.

Chedgy E, Lowe G, Tang R, Krebs C, Sawka A, Vaghadia H, Gleave ME, So AI.

Ann R Coll Surg Engl. 2018 Feb;100(2):120-124. doi: 10.1308/rcsann.2017.0169. Epub 2017 Oct 19.

PMID:
29046095
4.

Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study.

Struss WJ, Tan Z, Zachkani P, Moskalev I, Jackson JK, Shademani A, D'Costa NM, Raven PA, Frees S, Chavez-Munoz C, Chiao M, So AI.

Prostate. 2017 May;77(13):1356-1365. doi: 10.1002/pros.23395. Epub 2017 Aug 8.

PMID:
28786159
5.

Identifying intermediate-risk candidates for active surveillance of prostate cancer.

Savdie R, Aning J, So AI, Black PC, Gleave ME, Goldenberg SL.

Urol Oncol. 2017 Oct;35(10):605.e1-605.e8. doi: 10.1016/j.urolonc.2017.06.048. Epub 2017 Jul 20.

PMID:
28736249
6.

Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.

Han KS, Raven PA, Frees S, Gust K, Fazli L, Ettinger S, Hong SJ, Kollmannsberger C, Gleave ME, So AI.

Neoplasia. 2015 Nov;17(11):805-16. doi: 10.1016/j.neo.2015.11.001.

7.

A standardized protocol for identifying and counting lymph nodes harvested by pelvic lymph node dissection at the time of radical cystectomy.

Metcalfe MJ, Afshar K, So AI, Jones EC, Gilks BC, Black PC.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):337-42. doi: 10.5489/cuaj.2796.

8.

Balancing risk and benefit of extended pelvic lymph node dissection in patients undergoing radical cystectomy.

Abdi H, Pourmalek F, Gleave ME, So AI, Black PC.

World J Urol. 2016 Jan;34(1):41-8. doi: 10.1007/s00345-015-1734-x. Epub 2015 Nov 30.

PMID:
26621208
9.

Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2α pathway.

Han KS, Li N, Raven PA, Fazli L, Frees S, Ettinger S, Park KC, Hong SJ, Gleave ME, So AI.

Oncotarget. 2015 Oct 27;6(33):34818-30. doi: 10.18632/oncotarget.5397.

10.

Multiparametric magnetic resonance imaging-targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results.

Abdi H, Zargar H, Goldenberg SL, Walshe T, Pourmalek F, Eddy C, Chang SD, Gleave ME, Harris AC, So AI, Machan L, Black PC.

Urol Oncol. 2015 Apr;33(4):165.e1-7. doi: 10.1016/j.urolonc.2015.01.004. Epub 2015 Feb 7.

PMID:
25665509
11.

Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma.

Han KS, Li N, Raven PA, Fazli L, Ettinger S, Hong SJ, Gleave ME, So AI.

Mol Cancer Ther. 2015 Apr;14(4):1024-34. doi: 10.1158/1535-7163.MCT-14-0771. Epub 2015 Feb 5.

12.

Multiparametric magnetic resonance imaging enhances detection of significant tumor in patients on active surveillance for prostate cancer.

Abdi H, Pourmalek F, Zargar H, Walshe T, Harris AC, Chang SD, Eddy C, So AI, Gleave ME, Machan L, Goldenberg SL, Black PC.

Urology. 2015 Feb;85(2):423-8. doi: 10.1016/j.urology.2014.09.060.

PMID:
25623709
13.

Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.

Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR, Daneshmand S, Protheroe A, Tyldesley S, Black PC, Chi K, So AI, Moore MJ, Nichols CR.

J Clin Oncol. 2015 Jan 1;33(1):51-7. doi: 10.1200/JCO.2014.56.2116. Epub 2014 Aug 18.

PMID:
25135991
14.

DHH is an independent prognosticator of oncologic outcome of clear cell renal cell carcinoma.

Jäger W, Thomas C, Fazli L, Hurtado-Coll A, Li E, Janssen C, Gust KM, So AI, Hainz M, Schmidtmann I, Roos FC, Thüroff JW, Brenner W, Black PC.

J Urol. 2014 Dec;192(6):1842-8. doi: 10.1016/j.juro.2014.07.013. Epub 2014 Jul 18.

PMID:
25046620
15.

Urethral squamous cell papilloma: Case report and literature review.

Gustafson P, Fenster HN, So AI.

Can Urol Assoc J. 2014 May;8(5-6):E364-5. doi: 10.5489/cuaj.1582.

16.

Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration.

Bachir BG, Aprikian AG, Izawa JI, Chin JL, Fradet Y, Fairey A, Estey E, Jacobsen N, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Kapoor A, Matsumoto E, Saad F, Bell D, Black PC, So AI, Drachenberg D, Kassouf W.

Urol Oncol. 2014 May;32(4):441-8. doi: 10.1016/j.urolonc.2013.10.016. Epub 2014 Jan 10.

PMID:
24412632
17.

Surgery for treatment of metastatic testicular cancer.

Zargar H, Aning JJ, So AI.

ANZ J Surg. 2015 Mar;85(3):189-90. doi: 10.1111/ans.12392. Epub 2013 Oct 31. No abstract available.

PMID:
24171695
18.

The role of heat shock proteins in bladder cancer.

Ischia J, So AI.

Nat Rev Urol. 2013 Jul;10(7):386-95. doi: 10.1038/nrurol.2013.108. Epub 2013 May 14. Review.

PMID:
23670183
19.

Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach.

Jäger W, Moskalev I, Janssen C, Hayashi T, Awrey S, Gust KM, So AI, Zhang K, Fazli L, Li E, Thüroff JW, Lange D, Black PC.

PLoS One. 2013;8(3):e59536. doi: 10.1371/journal.pone.0059536. Epub 2013 Mar 26.

20.

Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa.

Jäger W, Horiguchi Y, Shah J, Hayashi T, Awrey S, Gust KM, Hadaschik BA, Matsui Y, Anderson S, Bell RH, Ettinger S, So AI, Gleave ME, Lee IL, Dinney CP, Tachibana M, McConkey DJ, Black PC.

J Urol. 2013 Oct;190(4):1404-9. doi: 10.1016/j.juro.2013.03.009. Epub 2013 Mar 7.

21.

Radical prostatectomy versus observation for prostate cancer.

Tyldesley S, McKenzie MR, So AI.

N Engl J Med. 2012 Oct 11;367(15):1468; author reply 1468-9. doi: 10.1056/NEJMc1209800#SA3. No abstract available.

PMID:
23050533
22.

The confusion surrounding prostate cancer screening faced by family physicians.

Hoag NA, So AI.

Can Urol Assoc J. 2012 Jun;6(3):194-5. doi: 10.5489/cuaj.12123. No abstract available.

23.

HIFU ablation is not a proven standard treatment for localized prostate cancer.

So AI.

Can Urol Assoc J. 2011 Dec;5(6):424-6. doi: 10.5489/cuaj.11232. No abstract available.

24.

Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium.

Mugabe C, Raven PA, Fazli L, Baker JH, Jackson JK, Liggins RT, So AI, Gleave ME, Minchinton AI, Brooks DE, Burt HM.

Biomaterials. 2012 Jan;33(2):692-703. doi: 10.1016/j.biomaterials.2011.09.081. Epub 2011 Oct 19.

PMID:
22014457
25.

Bladder cancer: are provider volumes a suitable measure of quality of care?

Casey RG, So AI.

Nat Rev Urol. 2011 Jun 14;8(7):361-3. doi: 10.1038/nrurol.2011.86. No abstract available.

PMID:
21670750
26.

In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.

Mugabe C, Matsui Y, So AI, Gleave ME, Baker JH, Minchinton AI, Manisali I, Liggins R, Brooks DE, Burt HM.

Clin Cancer Res. 2011 May 1;17(9):2788-98. doi: 10.1158/1078-0432.CCR-10-2981. Epub 2011 Feb 28.

27.

In vitro and in vivo evaluation of intravesical docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols in an orthotopic model of bladder cancer.

Mugabe C, Matsui Y, So AI, Gleave ME, Heller M, Zeisser-Labouèbe M, Heller L, Chafeeva I, Brooks DE, Burt HM.

Biomacromolecules. 2011 Apr 11;12(4):949-60. doi: 10.1021/bm101316q. Epub 2011 Mar 1.

PMID:
21355626
28.

The importance of integrin-linked kinase in the regulation of bladder cancer invasion.

Matsui Y, Assi K, Ogawa O, Raven PA, Dedhar S, Gleave ME, Salh B, So AI.

Int J Cancer. 2012 Feb 1;130(3):521-31. doi: 10.1002/ijc.26008. Epub 2011 May 28.

29.

Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death.

Zhang KX, Matsui Y, Hadaschik BA, Lee C, Jia W, Bell JC, Fazli L, So AI, Rennie PS.

Int J Cancer. 2010 Aug 15;127(4):830-8. doi: 10.1002/ijc.25088.

30.

The role of mTOR in bladder cancer.

Gust KM, So AI.

Cancer Biol Ther. 2009 Dec;8(24):2348-50. Epub 2009 Dec 9. No abstract available.

PMID:
19949304
31.

Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer.

Matsui Y, Hadaschik BA, Fazli L, Andersen RJ, Gleave ME, So AI.

Mol Cancer Ther. 2009 Aug;8(8):2402-11. doi: 10.1158/1535-7163.MCT-09-0148. Epub 2009 Jul 22.

32.

Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy.

Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, Burt HM.

BJU Int. 2009 Apr;103(7):978-86. doi: 10.1111/j.1464-410X.2008.08132.x. Epub 2008 Oct 31.

33.

Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer.

So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M.

Clin Cancer Res. 2008 Nov 1;14(21):6944-54. doi: 10.1158/1078-0432.CCR-08-0408.

34.

[Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].

Hadaschik BA, Zhang K, So AI, Bell JC, Thüroff JW, Rennie PS, Gleave ME.

Urologe A. 2008 Sep;47(9):1145-51. doi: 10.1007/s00120-008-1827-x. German.

PMID:
18670747
35.

Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.

Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC, Gleave ME, Rennie PS.

Cancer Res. 2008 Jun 15;68(12):4506-10. doi: 10.1158/0008-5472.CAN-08-0238.

36.

Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.

Hadaschik BA, ter Borg MG, Jackson J, Sowery RD, So AI, Burt HM, Gleave ME.

BJU Int. 2008 Jun;101(11):1347-55. doi: 10.1111/j.1464-410X.2008.07571.x. Epub 2008 Apr 2.

37.

Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer.

Hadaschik BA, Jackson J, Fazli L, Zoubeidi A, Burt HM, Gleave ME, So AI.

BJU Int. 2008 Aug 5;102(5):610-6. doi: 10.1111/j.1464-410X.2008.07669.x. Epub 2008 Apr 2.

38.

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.

Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME.

BJU Int. 2008 Aug;102(3):389-97. doi: 10.1111/j.1464-410X.2008.07618.x. Epub 2008 Mar 11.

39.

Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.

Hadaschik BA, Adomat H, Fazli L, Fradet Y, Andersen RJ, Gleave ME, So AI.

Clin Cancer Res. 2008 Mar 1;14(5):1510-8. doi: 10.1158/1078-0432.CCR-07-4475.

40.

A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging.

Hadaschik BA, Black PC, Sea JC, Metwalli AR, Fazli L, Dinney CP, Gleave ME, So AI.

BJU Int. 2007 Dec;100(6):1377-84. Epub 2007 Sep 10.

41.
42.

[Stress proteins in prostate cancer. Challenge and promise].

Hadaschik BA, Melchior SW, Sowery RD, So AI, Gleave ME.

Urologe A. 2007 May;46(5):516-20. Review. German.

PMID:
17372715
43.

Therapeutic options in advanced prostate cancer: present and future.

Sowery RD, So AI, Gleave ME.

Curr Urol Rep. 2007 Jan;8(1):53-9. Review.

PMID:
17239317
44.
45.

Androgens and prostate cancer.

So AI, Hurtado-Coll A, Gleave ME.

World J Urol. 2003 Nov;21(5):325-37. Epub 2003 Oct 29. Review.

PMID:
14586548

Supplemental Content

Support Center